3:41 PM
Jan 25, 2019
 |  BioCentury  |  Finance

Kurma’s Munich move

How French VC Kurma plans to turn German research into biotechs

Kurma Partners has opened a Munich office to spin out German academic science into biotechs in a bid to apply its company creation model to bridge the country’s venture capital gap for translating compelling research.

The new office reflects Kurma's shift to a pan-European incubation strategy with its Biofund III, for which the Paris-based firm raised an undisclosed amount in a first close announced in December. For its prior fund, the VC sought to connect French academic groups with an industry collaborator prior to building new companies (see “Spreading Good Kurma”).

“When we looked at how to expand in Europe, Germany was a clear spot for...

Read the full 512 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >